Properties
What is it?
Dosage Form: Solution for injection. Description: Clear, colorless or pale yellow solution. Composition: 1 ampoule of the preparation contains Active substance: Choline alfoscerate (in hydrate form) 1000 mg. Excipient: Water for injection. ATC code: N07AX02 Pharmacotherapeutic group: Nootropic preparation. Central-acting cholinomimetic. Pharmacological properties Pharmacodynamics: Central-acting cholinomimetic with predominant effect on the CNS. The preparation contains 40.5% metabolically protected choline. In the body, choline alfoscerate is broken down by brain enzymes into choline and alfoscerate, which is transformed into glycerophosphate. Choline participates in acetylcholine synthesis, thereby improving nerve impulse transmission, while glycerophosphate is a precursor of phosphatidylcholine in neuronal membranes, resulting in improved membrane elasticity and receptor function. Medotilin improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the brain's reticular formation, and restores consciousness in cases of traumatic brain injury. It has a prophylactic and corrective effect on the involutional processes of psychoorganic syndrome, such as changes in the phospholipid composition of the neuronal membrane and decreased cholinergic activity. See blog: Medotilin - a preparation that will help restore brain health. Pharmacokinetics: Medotilin easily crosses the blood-brain barrier, accumulating predominantly in the brain (45% of plasma concentration), as well as in the liver and lungs. It is mainly excreted through the lungs in the form of carbon dioxide (85%), with the remaining amount excreted through the kidneys and intestines. Indications for use: Acute period of craniocerebral trauma, predominantly with brainstem lesions (including impaired consciousness, comatose state); Ischemic (acute and recovery periods) and hemorrhagic (recovery period) cerebrovascular accidents; Degenerative and involutional psychoorganic syndromes, memory disorders resulting from cerebrovascular insufficiency, both primary and secondary, characterized by memory impairment, depressed consciousness, disorientation, decreased motivation and initiative, and impaired attention span; Emotional and behavioral disorders: emotional lability, irritability, decreased interest; Pseudodementia in the elderly; Multi-infarct dementia. Method of administration and dosage: The preparation is intended for intramuscular and intravenous administration. In acute cases, 1 g (1 ampoule) intramuscularly per day or 1 to 3 grams intravenously per day. For intravenous administration, the contents of 1 ampoule (4 ml) should be diluted in 50 ml of physiological saline; infusion rate is 60-80 drops/min. The duration of treatment is usually 10 days; if necessary, treatment can be continued until positive dynamics begin. Contraindications: Hypersensitivity to the components of the preparation; Pregnancy and lactation. Side effects: Nausea (due to stimulation of dopaminergic receptors), allergic reactions. As a rule, the preparation is well tolerated even with prolonged use. Use during pregnancy and lactation: The preparation is contraindicated during pregnancy. Breastfeeding should be discontinued during treatment with the preparation. Use in pediatrics: There is no experience with the use of Medotilin in children. Effect on ability to drive and operate machinery: Medotilin does not affect the ability to drive or perform other potentially hazardous activities. Interaction with other medicinal products: No interactions of Medotilin with other medicinal products have been described. Overdose: In case of overdose, nausea is observed, which subsides upon dose reduction or discontinuation of treatment. Release form: 4 ml of solution for injection in colorless glass ampoules. 3 ampoules in a contour cell package. The contour cell package is placed in a cardboard box with an insert leaflet. Storage conditions: Store in a place protected from moisture and light at a temperature not exceeding 25ºС. Keep out of reach of children. Shelf life: 4 years from the date of manufacture. Do not use after the expiry date. Dispensing conditions: Group II, prescription only.